Use of oral contraceptives, depot medroxyprogesterone acetate and intrauterine contraceptive devices and the risk of cancer

Authors

  • Dr. Chesang J.J

DOI:

https://doi.org/10.59692/jogeca.v29i1.351

Keywords:

Contraceptives, Cancer, OCs, DMPA, IUDs

Abstract

Background: The decision to use a contraceptive and the choice of method of contraception is partly informed by  its effects on the health of users. The impact of a contraceptive on the incidence of cancer may be regarded as of  greatest significance. 

Objective: To present a review of literature on the association between cancer and use of Oral Contraceptives (OCs),  Depot Medroxyprogesterone Acetate (DMPA)and Intrauterine Contraceptive Devices (IUDs).

Methods: This was a narrative review in which studies were identified through a search of the CINAHL, MEDLINE  and EMBASE databases. Included are studies assessing the association between cancer and OCs, DMPA or IUDs  published in English up to March, 2017. Overall, 27 studies were selected: 16 examined association with use of  OCs, eight assessed association with IUDs and eight with DMPA. Data from the selected studies were extracted as  reported in the studies. 

Results: Oral Contraceptives (OCs) are associated with a slight or no increase in the risk of breast cancer: 49 instead  of 44 per 10,000 women, confined to use within the last 10 years. However, OCs do not alter the risk of mortality  from breast cancer. Use of OCs for ≥5 years in the presence of HPV infection may increase the risk of and mortality  from cervical cancer. OCs are inversely associated with endometrial, colorectal and ovarian cancer (50%, 20-30%,  and 30-40% lower risk for ever- compared to never-use, respectively). Overall, there was a decrease in the incidence  of cancer by 10 to 45 per 100,000 women per year in OCs users. The association between DMPA and breast cancer  may be similar to that of OCs use. Overall, a higher risk of cancer (7% increase in incidence) has been reported in  levonorgestrel-releasing IUDs users.  

Conclusion: Use of OCs is associated with a lower risk of cancer. The association between cancer and use of  contraceptives other than OCs merits further assessment. 

Downloads

Published

2017-06-30

How to Cite

Chesang, J. (2017). Use of oral contraceptives, depot medroxyprogesterone acetate and intrauterine contraceptive devices and the risk of cancer. Journal of Obstetrics and Gynaecology of Eastern and Central Africa, 29(1), 11–16. https://doi.org/10.59692/jogeca.v29i1.351